Files and links (1)
Accepted (AM)Open Access (License Unspecified), Open
Journal article
Identification of a new class of small molecules that efficiently reactivate latent Epstein-Barr Virus
ACS chemical biology, v 9(3), pp 785-795
21 Mar 2014
PMID: 24028149
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Epstein-Barr Virus (EBV) persists as a latent infection in many lymphoid and epithelial malignancies, including Burkitt's lymphomas, nasopharyngeal carcinomas, and gastric carcinomas. Current chemotherapeutic treatments of EBV-positive cancers include broad-spectrum cytotoxic drugs that ignore the EBV-positive status of tumors. An alternative strategy, referred to as oncolytic therapy, utilizes drugs that stimulate reactivation of latent EBV to enhance the selective killing of EBV-positive tumors, especially in combination with existing inhibitors of herpesvirus lytic replication, like Ganciclovir (GCV). At present, no small molecule, including histone deacetylase (HDAC) inhibitors, have proven safe or effective in clinical trials for treatment of EBV-positive cancers. Aiming to identify new chemical entities that induce EBV lytic cycle, we have developed a robust high-throughput cell-based assay to screen 66,840 small molecule compounds. Five structurally related tetrahydrocarboline derivatives were identified, two of which had EC50 measurements in the range of 150-170 nM. We show that these compounds reactivate EBV lytic markers ZTA and EA-D in all EBV-positive cell lines we have tested independent of the type of latency. The compounds reactivate a higher percentage of latently infected cells than HDAC inhibitors or phorbol esters in many cell types. The most active compounds showed low toxicity to EBV-negative cells but were highly effective at selective cell killing of EBV-positive cells when combined with GCV. We conclude that we have identified a class of small molecule compounds that are highly effective at reactivating latent EBV infection in a variety of cell types and show promise for lytic therapy in combination with GCV.
Metrics
Details
- Title
- Identification of a new class of small molecules that efficiently reactivate latent Epstein-Barr Virus
- Creators
- Nadezhda Tikhmyanova - The Wistar InstituteDavid C Schultz - The Wistar InstituteTheresa Lee - The Wistar InstituteJoseph M Salvino - Drexel UniversityPaul M Lieberman - Drexel University
- Publication Details
- ACS chemical biology, v 9(3), pp 785-795
- Publisher
- American Chemical Society (ACS)
- Number of pages
- 11
- Grant note
- P30 CA 010815-42 / NCI NIH HHS R01 CA085678 / NCI NIH HHS P30 CA010815 / NCI NIH HHS T32 CA009171 / NCI NIH HHS R01 CA193624 / NCI NIH HHS 1T32 CA09171 / NCI NIH HHS
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pharmacology and Physiology
- Web of Science ID
- WOS:000333477300026
- Scopus ID
- 2-s2.0-84896929392
- Other Identifier
- 991021904614204721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Biochemistry & Molecular Biology